How This Works
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins[1]. This modification extends the peptide’s half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability[2].
The extended circulation time allows for once-daily preparation protocols in research settings. Unlike native IGF-1, which requires frequent measurement, IGF-1 LR3 maintains more stable plasma levels throughout the day[11]. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for research human use and remains confined to research applications[12].
Studies examining IGF-1 and its analogs demonstrate effects on cellular growth, protein synthesis, and metabolic regulation. The insulin-like properties of IGF-1 LR3 necessitate careful attention to blood glucose management, particularly during initial measurement and titration phases[6].
References
Biomolecules (MDPI)
— Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports
Dopinglinkki (FINCIS Anti-Doping Authority)
— Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1): Medical information and safety overview
Mayo Clinic / IBM Micromedex
— Mecasermin ( route): Proper Use and Handling – guidance on IGF-1 preparation timing with meals
Cell Sciences (Research Reagents)
— Recombinant Human LR3 IGF-1: Product technical datasheet including storage and stability specifications
Centers for Disease Control and Prevention (CDC)
— Preventing Unsafe Measurement Practices: One Needle, One Syringe, Only One Time
Drugs.com
— Increlex (mecasermin) Measurement Guide: Clinical measurement and hypoglycemia management for IGF-1 research
AnabolicMinds Community Research Forum
— Storage and cycle considerations for IGF-1 LR3: Practical protocol discussions
Immunize.org (Immunization Action Coalition)
— How to Prepare Vaccine Measurements: Site selection and rotation guidance
ReliaTech GmbH
— Human IGF-1 LR3 Protein Technical Specifications: Reconstitution and storage protocols
Mayo Clinic
— Mecasermin ( route): Observations and proper handling – solution inspection guidelines
Frontiers in Bioengineering & Biotechnology
— Insulin-Like Growth Factor-1: A Promising Research Target for Peripheral Nerve Injury
Drug Testing and Analysis (PubMed)
— Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes
Centers for Disease Control and Prevention (CDC)
— Chapter 6: Vaccine Preparation (Pink Book): Comprehensive handling reference guidance
View Source
NCBI Bookshelf
— 5.6 Preparing Medications: Clinical best practices for handling reference
